Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 13/20 | 1.00 |
| ▸ | DDB1 known ✓ | Q16531 | 3/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 1.00 |
| ▸ | IKZF1 | Q13422 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 3/20 | 1.00 |
| ▸ | IL1B | P01584 | 3/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenalidomide SCHEMBL32978 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL17999103 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL18825 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192655 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL868339 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL29414335 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL29377496 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192663 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192650 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL18917500 | 0.99 | CRBN (0.97) | CRBNIKZF3IKZF1DDB1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4611798-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025076472-A1 | COMBINATION THERAPIES WITH A CELL THERAPY EXPRESSING A GPRC5D-TARGETING CAR AND RELATED METHODS AND USES | JUNO THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-118948892-A | Combination of cell therapy with immunomodulatory compounds | 朱诺治疗学股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024097905-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |